LUX Breast 1 Cancer Clinical Trial

Nadia Harbeck

Interview with Nadia Harbeck, MD

Professor of Gynecology, Head Interdisciplinary Breast Center
Cologne/Frechen

Q. What is the rationale for conducting the LUX-Breast 1 trial?
A. Now the trial programme for afatinib* focuses completely on the HER2-positive tumours, so the idea is that the broader approach to targeting the HER-family is the more effective one and this is all with using a backbone of chemotherapy that is used in the practices quite often and is a very well-tolerated chemotherapy in that area.

Q. What is the trial programme for afatinib* in breast cancer?
A. We have a large registration trial Phase III trial, the LUX-1 trial, and we have an umbrella of smaller trials sort of covering difficult clinical situation like inflammatory breast cancer, like brain metastases on the side but the focus is on the registration trial.

*Afatinib is an investigational compound. Its safety and efficacy have not yet been fully established.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on